ReviewDrug design, development and therapy2026
Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Janus kinase inhibitors (JAKi) have undergone three decades of research and development, demonstrating substantial therapeutic efficacy and broad clinical applicability in autoimmune diseases, inflammatory disorders, hematopoietic malignancies, and a spectrum of rare diseases. However, their research and development are constrained by three key challenges: the difficulty in target selection and safety concerns arising from their effects on cellular signaling pathways, as well as the challenges in formulating optimal dosing regimens due to interindividual variability in pharmacokinetics. In this study, we systematically investigated the global development trends and pipeline evolution of JAKi from 1995 to 2025. A total of 271 JAKi candidates with 2035 associated clinical trials were identified to date. Clinical trial activity has risen rapidly since 2018 and remains robust. Phase III trials accounted for 26% of all studies, while 52% were in early-phase (Phase I/II) research, underscoring considerable potential for future development in this field. Immune-mediated inflammatory diseases and hematopoietic malignancies emerged as the leading therapeutic areas, representing 69.3% and 14.0% of all indications, respectively. Notably, rare diseases constituted 35.8% of the indications targeted by JAKi, with 20.4% of clinical trials focusing on these conditions. We comprehensively analyzed the multifaceted drivers underlying these developmental trends, with a specific emphasis on rare disease applications. Additionally, we critically evaluated the key challenges encountered in JAKi research and development, aiming to provide strategic insights to guide future investigations in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.